Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY26 Earnings Presentation
31 slides from Dr. Lal Pathlabs's earnings presentation, Apr 30, 2026
Slide 1: Exchange cover letter for earnings presentation
April 30, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earnings P
Slide 2: Results Presentation Q4 FY26 & FY26
Results Presentation Q4 FY26 & FY26
Slide 3: Disclaimer
By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentations by the
Slide 4: Table of Contents
Table of Contents DLPL - At a Glance 4 Q4 FY26 Performance Overview 5 Financials 7 Key Performance Highlights 8 Management Commentary 10 Shareholding 15 Corporate Overview 17 Contact Us 29 DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operat
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 75+ years of experience India’s Leading & 141 Mn patients 53 NABL & 2 CAP in the field of Trusted Diagnostics serviced in last 5 years accredited Labs diagnostics Company 7,700+ 4,800+ 312 Patient Service Centers Pathology, Radiology tests & Panels; Labs; Geographicall
Slide 6: Q4 FY26 Performance Overview
Q4 FY26 Performance Overview Q4 FY26 Q4 FY25 Gr% Revenue (Rs. Cr.) 703 603 16.6% EBITDA before exceptional items 187 169 10.5% (Rs. Cr.) PAT before exceptional items 132 115 15.1% (Rs. Cr.) Patients(Mn) 7.4 6.8 8.2% Samples(Mn) 23.6 20.9 12.9% SwasthFitTM 28% 26% +2% Contribution 5
Slide 7: FY26 Performance Overview
FY26 Performance Overview FY26 FY25 Gr% Revenue (Rs. Cr.) 2763 2461 12.2% EBITDA before exceptional items 783 696 12.5% (Rs. Cr.) PAT before exceptional items 532 451 17.9% (Rs. Cr.) Patients(Mn) 30.3 28.8 5.3% Samples(Mn) 94.5 85.6 10.4% SwasthFitTM 27% 24% +3% Contribution 6
Slide 8: Financials
Financials Reported Results (Rs. Cr.) Q4 FY26 Q4 FY25 Gr % FY26 FY25 Gr % Revenue 703 603 16.6% 2,763 2,461 12.2% Material consumed 135 118 535 481 Employee benefit Expenses 129 109 533# 456 Fees to collection centres 101 78 402 342 Other Expenses 151 129 540 487 EBITDA 187 169 10.5% 752 696 8.2% Ma
Slide 9: Key Performance Highlights
Key Performance Highlights Steady topline momentum: Delivered revenue of Rs. 703 crore in Q4 FY26, a growth of 16.6%. Revenue growth is 12.2% for full year FY26. • Highest quarterly Revenue growth in Last 16 Quarters • Revenue growth fueled by strong volume momentum (+12.9% Y-o-Y sample volumes for
Slide 10: Operating highlight
Operating highlight No. of Clinical Laboratories No. of PSCs No. of PUPs +35 +2,625 +2,997 312 13,935 280 298 12,365 277 7,727 11,619 10,938 6,607 5,762 5,102 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 No. of Patients (Mn) No. of Samples (Mn) +3.4 +22.2 85.6 94.5 30.3 78.2 26.9 27.6
Slide 11: Management Commentary
Management Commentary Mr. Ved Goel, (Hony.) Brig. Dr. Arvind Lal, Mr. Shankha Banerjee, Group CFO & Padma Shri Chief Executive Officer CEO – International Executive Chairman Business Commenting on the performance, Mr. Shankha Banerjee, Commenting on the performance, Mr. Ved Prakash Commenting on the
Slide 12: Robust financial performance
Robust financial performance (INR Cr.) (INR Cr.) (INR Cr.) Revenue Cash and Cash Equivalents EBITDA, PAT and ROCE EBITDA PAT 1,526 2,763 2,461 1,229 783# 2,227 696 2,017 609 877 490 532# 492 601 362 241 F Y 23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 EBITDA 24.3% 27.4% 28.3% 28.3% Marg
Slide 13: Expanding Revenue Footprint Across Emerging Markets
Expanding Revenue Footprint Across Emerging Markets Revenue Tier 3+ CAGR 16.7% Geography wise Revenue South India Others 6% 2% West India DNCR 14% 31% Revenue by Geography East FY26 India 15% UP & UK Rest of 19% North 13% (INR Cr.) (INR Cr.) 12
Slide 14: Medllumina: First International Medical Conference by DLPL
Medllumina : First International Medical Conference by DLPL Conference Advancing Precision Diagnostics Podcast Series Platform for Collaboration for Clinicians, Global Thought Leaders & Pathologists Case Study Integrating AI and Next-Gen Technology Digital Engagement Newsletter Clinician Engagement
Slide 15: Research & Academic collaborations
Research & Academic collaborations Academia Partnerships Collaborations In House Sustainability • Fundamental Research • Novel Solutions • Educational Initiatives • Improve Core Processes • DOCTORAL & Multi • Clinical Trials • 49 ethics-approved • Contribute to ESG Omics Projects projects Initiative
Slide 16: Shareholding as of 31st March, 2026
Shareholding as of 31st March, 2026 17.47% FPI’s & NRI’s 53.21% 10.42% Promoter and Others Promoter Group 18.90% Mutual Funds* 15 *Mutual Funds includes Alternate Investment Funds as well
Slide 17: Key Awards & Recognition
Key Awards & Recognition Outstanding Contribution Rotary India National CSR Award in Healthcare from India 2030 Leadership Brand Honchos’ Indian Social Rotary India National CSR The CFO of the year 2026 Awards-National Level Foundation for Quality (India) Conclave 2026 Impact Awards-National Level A
Slide 18: Corporate Overview
Corporate Overview NATIONAL REFERENCE LAB KOLKATA REFERENCE LAB BENGALURU REFERENCE LAB MUMBAI REFERENCE LAB 17
Slide 19: Indian Healthcare Services is a large and growing opportunity
Indian Healthcare Services is a large and growing opportunity Healthcare expenditure as % of GDP 4 Healthcare spend – Developed Countries ~1.51 bn 5% India’s expected population India’s projected spend on in 20301 healthcare (as % of GDP) in FY305 India, highly 11.2 Canada 16.5 USA 11.9 France 12.6
Slide 20: Drivers of India diagnostic services market
Drivers of India diagnostic services market Lifestyle Diseases Longer Lifespans Preventive Checkups Growth Higher GDP per capita Drivers Evidence based treatment Govt. Spend on Primary Healthcare 19
Slide 21: Diagnostic Services industry continues to remain highly fragmented
Diagnostic Services industry continues to remain highly fragmented Highly Fragmented Industry Standalone Centres Regional Chains 42-46% 55% 16-20% Diagnostic Chains 45% 36-40% Hospital Based Labs Multi-Regional Source: Industry Data 20
Slide 22: Our Evolution
Our Evolution • Investment in Illumina Novaseq • 1949: Founded by Dr. Major • Higher contribution from Rest Platform S. K. Lal of India business & focus on • Launch of Sovaaka – AI powered bundled test program precision Health Screening • 1995: Company incorporated “Swasthfit” as Dr. Lal PathLabs Pr
Slide 23: Most trusted healthcare brand in Diagnostic Services
Most trusted healthcare brand in Diagnostic Services 30.3M+ Patients Serviced in FY26 13,900+ Coverage in 24x7 access Centrally Pick-up Points Accreditations metros, Wide reach including administered Dedicated from CAP, Tier 1, Tier 2 through PSCs online access surveillance logistics team NABL and I
Slide 24: Collection network
Collection network LPL’s scalable business model provides strategic advantage for expansion and consolidation National Reference Lab & Regional Ref. Lab Regional Reference Lab Single brand pulls patients Clinical Labs (Testing/Collection) Walk-in customers account for Patient Service Centers Pick-up
Slide 25: DLPL Strategy for future growth
DLPL Strategy for future growth Patient AI Technology New Revenue Experience Models Scientific Merger & Leadership Acquisitions Operational International Excellence Business People 24
Slide 26: Unleashing Digital Transformation: Driving Efficiency & Elevating Customer Experience
UNLEASHING DIGITAL TRANSFORMATION: DRIVING EFFICIENCY & ELEVATING CUSTOMER EXPERIENCE Operations Consumers Medical • GenAl & curated • Unified Communication • Smart Culture healthcare models Engine Reporting: Advancing managing interactions Quality through Data- • WhatsApp as forefront Driven Report
Slide 27: Cyber Security Capability
Cyber Security Capability Extended Detection Threat Data Loss Training on Security Operations Software Security & Response Center Intelligence Prevention Information Security • SASE - Secure • Vulnerability • Data classification • Periodic • Security • Digital Risk Access Service Assessment & platfo
Slide 28: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 98.1% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.2% for Satellite Labs CAP accreditation 2 labs, NABL accreditation 53 labs 100+ Quality NABL improvement Tech Assure
Slide 29: Key ESG Initiatives
Key ESG Initiatives 42 KW Solar System Installed for generating the green energy in existing 3.18 MW base Use of Electric bikes for sample collection Saved 2515 Metric ton of CO2 emissions by using Solar power Use of biodegradable bags for sample collection Installed R32 refrigerant operated Inverte
Slide 30: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests
Slide 31: Thank You
Thank You 30